Welcome to our dedicated page for Astria Therapeutics news (Ticker: ATXS), a resource for investors and traders seeking the latest updates and insights on Astria Therapeutics stock.
Astria Therapeutics, Inc. (NASDAQ: ATXS) generates news primarily as a clinical‑stage biopharmaceutical company focused on allergic and immunologic diseases. Company updates center on its lead investigational therapy navenibart (STAR‑0215), a monoclonal antibody inhibitor of plasma kallikrein in development for hereditary angioedema (HAE), and on STAR‑0310, an investigational OX40 antagonist in development for atopic dermatitis.
News items about Astria often highlight progress in its clinical programs. For navenibart, this includes announcements on the ALPHA‑STAR Phase 1b/2 trial results in HAE patients, the global ALPHA‑ORBIT Phase 3 randomized, double‑blind, placebo‑controlled trial, and the ORBIT‑EXPANSE long‑term extension trial where all participants receive navenibart on every‑three‑month or every‑six‑month dosing schedules. Press releases have described attack‑rate reductions, safety and tolerability findings, and patient‑reported quality‑of‑life measures, as well as enrollment milestones and trial site activations across multiple regions.
Coverage also includes early‑stage results for STAR‑0310, where Astria has reported Phase 1a data in healthy subjects, including extended half‑life, durable cytokine inhibition over 16 to 20 weeks, and the absence of antibody‑dependent cellular cytotoxicity‑related side effects in the data presented. These updates are frequently tied to scientific and medical conferences in allergy and dermatology.
In addition, Astria’s news flow features corporate and strategic developments such as the definitive merger agreement with BioCryst Pharmaceuticals, Inc., under which BioCryst has agreed to acquire Astria for a mix of cash and stock, and a license agreement with Kaken Pharmaceutical Co., Ltd. for navenibart rights in Japan. Investors following ATXS news can expect a mix of clinical trial readouts, regulatory and collaboration announcements, financial updates, and transaction‑related disclosures.
Astria Therapeutics, Inc. (NASDAQ: ATXS) announced on April 1, 2022, the grant of equity awards under its 2022 Inducement Stock Incentive Plan. The awards, totaling options for 32,500 shares of common stock, were given to new employees as an incentive. Each option has an exercise price of $6.48, matching the closing stock price on the grant date. The options will vest over four years, contingent upon the employees' continued employment. Astria focuses on developing therapies for rare allergic and immunological diseases, with its lead program being STAR-0215 for hereditary angioedema.
Astria Therapeutics, Inc. (NASDAQ:ATXS) reported its financial results for Q4 and full year 2021, alongside updates on its STAR-0215 therapy for hereditary angioedema (HAE). The company plans to file an IND application for STAR-0215 mid-year and initiate a Phase 1a clinical trial with initial results expected by year-end. As of December 31, 2021, cash and equivalents totaled $125.5 million. The net loss for 2021 was $194.9 million, significantly impacted by a $164.6 million in-process R&D expense from acquiring Quellis Biosciences.
Astria Therapeutics (NASDAQ:ATXS) announced participation in two investor conferences. The company will present on March 17, 2022, at Oppenheimer’s 32nd Annual Healthcare Conference, featuring CEO Jill C. Milne discussing their lead program STAR-0215 for hereditary angioedema. Additionally, Astria will be involved in the Guggenheim Healthcare Talks on March 31 and April 1, 2022. A live webcast of the Oppenheimer presentation will be available, with an archive accessible for 30 days post-event. Astria Therapeutics is focused on developing therapies for rare allergic and immunological diseases.
Astria Therapeutics (NASDAQ:ATXS) announced it will present new preclinical data for its drug candidate STAR-0215 at the AAAAI Annual Scientific Meeting in Phoenix, Arizona, on February 28, 2022. STAR-0215 is a long-acting monoclonal antibody designed to treat hereditary angioedema (HAE) by inhibiting plasma kallikrein, with a dosing schedule of once every three months or longer. After filing an IND application mid-2022, Astria plans to initiate a Phase 1 trial with initial results expected by year-end.
Astria Therapeutics (NASDAQ:ATXS) reported Q3 2021 financial results and company updates, highlighting the development of STAR-0215 for hereditary angioedema (HAE). The company aims to reduce patient treatment burden with less frequent dosing. They expect initial Phase 1 clinical trial results by year-end 2022. As of September 30, 2021, Astria had $131.8 million in cash, sufficient to finance operations through 2023. Q3 net loss improved to $7.9 million, down from $10.9 million in Q3 2020, with a net loss per share of $0.61.
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical firm, announced that CEO Jill C. Milne, Ph.D., will present information on their lead program STAR-0215 at the Jefferies London Healthcare Conference. The presentation will be available on-demand from November 18, 3:00 am ET to November 19, 12:00 pm ET. Attendees can access the webcast via the Investors section of Astria's website and at this link. An archived replay will be available for 30 days following the event.
Astria Therapeutics (NASDAQ:ATXS) presented new preclinical data for STAR-0215, a monoclonal antibody targeting hereditary angioedema (HAE), showing it binds to plasma kallikrein with ten-fold greater potency than lanadelumab. The study revealed STAR-0215's extended plasma half-life of about 34 days, allowing for potential dosing every three months. This profile supports its aim to be a patient-friendly treatment option. The company plans to file an Investigational New Drug application for STAR-0215 in mid-2022, with initial Phase 1 trial results expected by year-end 2022.
Astria Therapeutics, Inc. (NASDAQ:ATXS) is set to release its third quarter 2021 financial results on November 10, 2021, before the market opens. The CEO, Jill C. Milne, will host a conference call at 8:30 am ET to discuss the results and ongoing corporate developments. Known for its lead program STAR-0215, which targets hereditary angioedema, Astria aims to provide innovative therapies for rare immunological diseases. Investors can participate via a toll-free dial-in number or by accessing a live webcast on the company's website.
Astria Therapeutics, Inc. (NASDAQ:ATXS) announced new preclinical results for its lead program, STAR-0215, aimed at treating hereditary angioedema (HAE). These results will be presented at the 2021 American College of Allergy, Asthma and Immunology Annual Scientific Meeting in New Orleans on November 5, 2021, by Chief Scientific Officer Andrew Nichols. STAR-0215 is a monoclonal antibody plasma kallikrein inhibitor still in preclinical development.
Astria Therapeutics (NASDAQ:ATXS) presented significant findings at the 2021 NORD Rare Diseases and Orphan Products Breakthrough Summit, highlighting a substantial need to alleviate both the disease and treatment burden for hereditary angioedema (HAE) patients. Interviews with ten HAE patients revealed that they desire therapies with similar efficacy but less frequent dosing. The company aims to address these needs through its preclinical program, STAR-0215, which could offer a patient-friendly option with dosing every three months or longer.